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Supplementary Material 
On re-analysis of the three meta-analyses 9-11 following publication of the ASCOT-BPLA 
trial8 , we found an inconsistency amongst trials that were either included or excluded by 
the respective meta-analyses.  Of note none of the analyses took into account blood 
pressure differences, which is an important omission as may explain discrepancies in 
the relative risk reduction which could be accounted for by BP differences. We therefore 
present here a sensitivity analysis using the Lindholm et al.9, analysis as a baseline, and 
including first trials that this analysis excluded (VAACS/AASK/CAAP S1-3), second by 
excluding trials from Lindholm et al., where there is non-random allocation to β-
blockersS3-6 , rather random allocation was to the “conventional” drug, where the treating 
physician was allowed to choose between diuretics or β-blockers and third present an 
analysis that includes all the randomised studies. All analyses are based on stroke as an 
outcome, as this was the major factor in informing the change in guidance with respect 
to pharmacological management of blood pressure. In parallel with these outcome 
based analyses we also present changes in systolic blood pressure which can account 
for the differences seen in relative risk of stroke. Trial by trial analyses for stroke and BP 
are shown in Supplementary Figure 1, and these are summarised in Supplementary 
Figure 2. 
 
Supplementary Methods 
Meta-analysis 
Search Strategies: References within the cited meta-analyses9-11 were used to extract 
data from and carry out the meta-analyses, to specifically assess the change in the 
relative risk estimate of stroke by adding or taking away studies either included or 
excluded by published meta-analyses. Data extracted included study design (details of 
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mean follow up, if intention to treat analyse were used, procedures of randomisation), 
number of patients per arm, outcomes of stroke, myocardial infarction and all cause 
mortality. Data was extracted by two independent researches (RS and JPC). Blood 
pressure measures collected were those pre-treatment and those at the end of the trial 
duration. For ASCOT-BPLA the average BP difference reported over the course of the 
trial was used for analyses.  
 
Statistical analysis: The effect of β-blockers on blood pressure was calculated by the 
difference in the change in mean values between the beta blocker arm and the 
alternative treatment regime. Blood pressure values and standard deviations (SD) were 
used for these calculations, where SDs were not given, SDs from the largest study were 
used. Study specific estimates were weighted by the inverse of the variance and pooled 
by random effects meta-analysis to generate summary effects. Similarly for outcomes, β-
blockers were compared to other treatment regimes and summary relative risks for 
outcomes of stroke, MI and all cause mortality were estimated using random effects 
meta-analysis.  
 
Overlapping distributions: Reported means and SD from the ASCOT-BPLA trial were 
used to generate overlapping distribution curves, to assess the difference in the actual 
levels of glucose in both treatment arms and to calculate an odds ratio from this. Post 
treatment glucose levels were calculated from addition of the change from baseline to 
final visit to the baseline levels. Standard deviations of the post treatment glucose were 
not reported, and therefore pre-treatment SDs were used and were assumed to be equal 
(SD=2.12 was used for calculations). Distributions were assumed to be normal. These 
summary data (means and SDs) were then used to construct normal distributions of 
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glucose for those treated with the amlodipine based regime and those treated with the 
beta blocker based regime. Odds ratios were estimated as described in Wald NJ et al 
1999(S7). In brief, taking 7 mmol/ l as the cut off for diagnosis of diabetes, the proportion 
of individuals over this level was calculated using standard one tailed z tables. Odds of 
those affected compared to those unaffected for each treatment group was compared 
and were then used to generate odds of developing diabetes in those treated with the 
atenolol based regime compared to those treated with amlodipine based regime.  
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Supplementary Figure 1 
The left hand panel of forest plots shows relative risk of stroke, the right hand panel 
shows weighted mean difference in Systolic blood pressure in the same studies, an 
analysis which was not included in previously published meta-analyses. The baseline 
analysis considered here is the Lindholm et al analysis, which is shown in Figures 1a 
and b, sensitivity analyses are then performed based on this as a baseline, first to 
include studies that were excluded in Lindholm et al (VACS, AASK, CAPP) Figures 1c 
and d; second, based on Lindholm et al but excluding studies where treatment allocation 
was non randomised (NORDIL/ CONVINCE and STOP2) in Figures 1 e and f, and finally 
randomised studies in one analysis Figures 1g and 1h.  
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AASK African American Study of Kidney Disease and Hypertension, CAPPP Captopril Prevention Project, NORDIL 
Nordic Diltiazem Study, CONVINCE Controlled Onset Verapamil Investigation of Cardiovascular Endpoints, STOP2 
Swedish Trial in Old Patients with Hypertension, VACS Veterans Administration Cooperative Study 
 
6 
 
Supplementary Figure 2a 
Summary plots of the pooled risk ratio for stroke in trials of beta-blockers varies 
depending on the trials included/ excluded in the analyses  
 
(a) Lindholm L et al Baseline analysis
(b) Linholm L  et al  including VACS/ AASK/ CAPP
(c) Lindholm L et al  excluding NORDIL/ CONVINCE/ STOP2
(d) Lindholm l et al including VACS/ AASK/ CAPP and 
Excluding NORDIL/CONVINCE/ STOP 2
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Supplementary Figure 2b 
Summary plot of the difference in systolic blood pressure (SBP (mmHg) corresponding 
to the stroke end-point analysis reported in Figure 2a. In all scenarios, the BP difference 
favours the comparator drug over β-blockers. Percentage reduction in stroke risk is 
calculated from what is expected from the calculated blood pressure difference (see 
Staesson et al 2005, Reference 13 in main manuscript) 
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Supplementary Figure 3 
Estimated distribution of on treatment blood glucose values in patients randomised to 
amlodipine and atenolol in the ASCOT-BPLA trial based reported mean (SD)8 . The 
relative odds ratio of diabetes in those taking β-blockers vs amlodipine, using a cut off of 
7 mmol/l glucose for the diagnosis of diabetes is 1.18. The reported relative risk for 
diabetes was 0.70 (95% CI 0.63, 0.78) in favour of the amlodipine based regime. 
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Supplementary Figure 4  
Non-linear relationship between mean fasting blood glucose and risk of CHD or stroke 
from the Emerging Risk Factors Collaboration21 
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